MA-LINEDATA
16.3.2021 08:32:07 CET | Business Wire | Press release
Linedata, a global provider of credit and asset management technology, data and services, today announced it is the first technology vendor to seamlessly integrate Environmental, Social, and Governance (ESG) data into asset managers’ workflows through collaboration with leading independent provider Arabesque S-Ray . A wide range of ESG data assets feeds directly into Linedata’s software to help managers meet growing demands from regulators and investors for greater transparency over ESG funds, and to provide a competitive edge through sustainable positioning and differentiated product offerings.
Arabesque S-Ray’s quantitative data tool uses machine learning to crunch the sustainability performance of over 8,000 of the world’s largest listed companies, and directly integrates with Linedata’s portfolio and order management solutions for unparalleled ease of use. It is available to Linedata clients in Europe, Asia, and North America.
“We believe economic value creation can go hand in hand with environmental stewardship, social inclusion, and sound governance,” noted Georg Kell, Chairman of the Arabesque Group, and founding Executive Director of the United Nations Global Compact. “Our agreement with Linedata empowers more asset managers to make better decisions for a sustainable future.”
Positioning powerful ESG intelligence at the fingertips of Linedata’s over 450 global asset management clients helps managers support ESG decision-making and adapt to evolving requirements under Europe’s new Sustainable Finance Disclosure Regulation (SFDR) and the United States’ new ESG agenda.
The move also marks an expansion of Linedata’s Data Management Service, a key component of its cloud-based Asset Management Platform - AMP launched last year. It offers an innovative commercial model which gives basic ESG and UN Global Compact scores to users of Linedata software, and the flexibility to access premium data on a usage basis, a break from the industry standard.
“Linedata is committed to helping market participants to make more and better ESG driven decisions. With sustainable fund assets hitting a record $1.7 trillion in 20201 , asset managers recognize ethical and sustainable funds as a major growth opportunity,” said Gary Brackenridge, Linedata’s Global Head of Asset Management. “The combination of Arabesque’s market-leading ESG data seamlessly integrated into Linedata’s cloud-based portfolio workflows with a unique usage model fits with what we know clients are looking for: commercial flexibility, high-value content and excellent user experience.”
Providing instant access to Arabesque S-Ray’s data supports the wider industry shift to ESG investing, while removing a major operational burden from asset managers. The ability to leverage independently validated ESG scores streamlines and accelerates the development of ethical, sustainable and funds and in turn helps guide which companies consciously minded investors and consumers choose to support.
Users benefit from ESG data insights throughout the entirety of their investment operations:
- Score, rebalance, and create new ESG portfolio strategies, products, and workflows
- Integrate ESG factors into pre- and post-trade Compliance at asset and fund level
- Manage regulatory and investor transparency and reporting with dashboards, screening, and monitoring tools
To learn more about Linedata’s Data Management Service - ESG Inside, visit linedata.com/ESG
Linedata is pleased to have won Best Data Management Solution at Hedgeweek European Awards 2021 at a virtual gala on Thursday March 11, 2021.
1 Sustainable investment indexes outperform and protect on the downside: Morningstar , 16.02.21
ABOUT ARABESQUE S-RAY
S-Ray® is an AI-based tool developed by Arabesque that analyses the sustainability performance of approximately 8,000 of the world’s largest listed corporations using self-learning quantitative models and data scores. The technology systematically combines over 200 ESG metrics with news signals from over 30,000 sources across 170 countries. It is the first tool of its kind to rate companies on the normative principles of the United Nations Global Compact (GC Score). Additionally, S-Ray provides an industry-specific assessment of companies’ performance on financially material sustainability criteria (ESG Score). Both scores are combined with a preferences filter that assesses a company’s business involvements. S-Ray daily data products and services are used by some of the world’s leading financial institutions, investors, corporations, and consultants.
ABOUT LINEDATA
With 20 years’ experience and 700 clients in 50 countries, Linedata’s 1100 employees in 20 offices provide global humanized technology solutions and services for the asset management and credit industries that help its clients to evolve and to operate at the highest levels.
Headquartered in France, Linedata achieved revenues of EUR 161.0 million in 2020 and is listed on Euronext Paris compartment B FR0004156297-LIN – Reuters LDSV.PA – Bloomberg LIN:FP.
linedata.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210316005350/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
